Epaminurad is an investigational urate-lowering agent that functions as a selective inhibitor of the human urate transporter 1 (hURAT1). By inhibiting this transporter in the renal proximal tubule, the… Read more
Epaminurad is an investigational urate-lowering agent that functions as a selective inhibitor of the human urate transporter 1 (hURAT1). By inhibiting this transporter in the renal proximal tubule, the compound works to reduce uric acid reabsorption, positioning it as a potential therapeutic option for the treatment of gout and hyperuricemia. Laboratories involved in pharmaceutical research rely on high-quality reference standards, metabolites, and stable isotope-labelled compounds of Epaminurad to ensure accuracy throughout the development pipeline. These analytical tools are essential for rigorous impurity profiling, method validation, and quality control, allowing researchers to monitor degradation products and quantify active drug levels with precision. By utilizing these specialized reference materials, analytical chemists can maintain consistency and regulatory compliance while evaluating the efficacy and safety profile of this drug candidate during preclinical and clinical stages.